scispace - formally typeset
T

Thomas Simmet

Researcher at University of Ulm

Publications -  211
Citations -  15559

Thomas Simmet is an academic researcher from University of Ulm. The author has contributed to research in topics: Proinflammatory cytokine & Monocyte. The author has an hindex of 54, co-authored 202 publications receiving 13691 citations. Previous affiliations of Thomas Simmet include University of Freiburg & French Institute of Health and Medical Research.

Papers
More filters
Journal ArticleDOI

Oleanolic acid methyl ester, a novel cytotoxic mitocan, induces cell cycle arrest and ROS-Mediated cell death in castration-resistant prostate cancer PC-3 cells.

TL;DR: In vivo, OAME exerted concentration- dependent antiproliferative effect, associated with a significant level of apoptosis, potent antiangiogenic activity, and downregulation of survivin, suggesting that OAME might serve as a promising lead compound to treat hormonal-resistant prostate cancer.
Journal ArticleDOI

Hexon Modification to Improve the Activity of Oncolytic Adenovirus Vectors against Neoplastic and Stromal Cells in Pancreatic Cancer

TL;DR: To increase activity of replicating Ad vectors, it is proposed to relax tumor cell selectivity by genetic hexon-mediated targeting to the TGFBR to enable replication also in the stromal cell compartment of tumors, while abolishing hepatocyte transduction, and thereby increasing safety.
Journal ArticleDOI

Acetyl-lupeolic acid inhibits Akt signaling and induces apoptosis in chemoresistant prostate cancer cells in vitro and in vivo

TL;DR: Ac-LA exhibited antiproliferative, proapoptotic, and antitumorigenic effects on PC-3-tumors xenografted either on chick chorioallantoic membranes or in nude mice, and exhibited a clearly better safety profile than docetaxel or lupeol during chronic administration in vivo.
Journal ArticleDOI

B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21

TL;DR: It is demonstrated that treatment of B-CLL cells with CpG and IL-21 results in the development of antigen-presenting cell (APC)-like cells with cytotoxic features, which result in enhanced immunogenicity, cytotoxicity and apoptosis.